pertuzumab
Trade name: perjeta
mAbapproved
Approved
Jun 8, 2012
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. — Wikipedia
Clinical trial activity
294 trials · 254 clinical orgs · 3 marketing orgs
Phase 1
56
Phase 2
229
Phase 3
70
Phase 4
7
Earliest trial started Nov 1, 2001 (NCT00027027)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Adrenal Gland Neoplasms · Phase 2
- Anemia · Phase 1
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Brain Neoplasms · Phase 2
- Breast Diseases · Phase 1/Phase 2
- Breast Neoplasms, Male · Phase 1
- Carcinoid Tumor · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Early Phase 1
- Cholangiocarcinoma · Phase 2
- Colonic Neoplasms · Phase 3
- Colorectal Neoplasms · Phase 2/Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Drug Therapy · Phase 2
- Endometrial Neoplasms · Phase 2/Phase 3
- Epidermal Growth Factor · Phase 2
- ErbB Receptors · Phase 2
- Esophageal Neoplasms · Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2/Phase 3
- Gastrointestinal Neoplasms · Phase 2
- Genes, erbB-2 · Phase 1
- Glioma · Phase 2
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 2
- Hemangiosarcoma · Phase 2
- Hodgkin Disease · Phase 1
- Hypertrophy, Left Ventricular · Phase 2
- Inflammatory Breast Neoplasms · Phase 3
- Kidney Neoplasms · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2/Phase 3
- Lymphoma · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Melanoma · Phase 2
- Meninges · Phase 1/Phase 2
- Multiple Endocrine Neoplasia · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplastic Cells, Circulating · Phase 2
- Neuroblastoma · Phase 2
- Neuroendocrine Tumors · Phase 2
- Ovarian Neoplasms · Phase 3
- Pancreatic Neoplasms · Phase 2/Phase 3
- Pharmacokinetics · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Primary Myelofibrosis · Phase 1
- Progression-Free Survival · Phase 2
- Prostatic Neoplasms · Phase 2/Phase 3
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Rectal Neoplasms · Phase 2
- Renal Colic · Phase 2
- Rocky Mountain Spotted Fever · Phase 3
- Salivary Gland Neoplasms · Phase 2/Phase 3
- Sarcoma · Phase 2
- Skin Neoplasms · Phase 2/Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 3
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2/Phase 3
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2/Phase 3
Mechanism of action
ERBB2 inhibitor
Approval history
- approvedJun 8, 2012
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaPertuzumab ↗
- NCATSK16AIQ8CTM ↗
- ChEMBLCHEMBL2007641 ↗
Also known as
- 2c4 antibody
- moab 2c4
- monoclonal antibody 2c4
- omnitarg
- omnitarg
- omnitarg, 2c4
- omnitarg perjeta
- perjeta
- perjeta
- perjeta
- perjeta
- perjeta
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- pertuzumab
- rg-1273
- rhumab 2c4
- rhumab-2c4
- rhumab-2c4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294508 | Phase 2/Phase 3 (Phase 3) | Jan 25, 2026 | Shanghai Henlius Biotech |
| NCT07299890 | Phase 2 | Dec 20, 2025 | Anhui Medical University |
| NCT07245797 | Phase 2 | Dec 15, 2025 | Fudan University |
| NCT07246317 | Phase 2 | Dec 15, 2025 | Tianjin Medical University |
| NCT07129018 | Phase 2 | Nov 30, 2025 | Eastern Hepatobiliary Surgery Hospital, Huazhong University of Science and Technology |
| NCT07220135 | Phase 2 | Nov 14, 2025 | University of Kansas |
| NCT07196774 | Phase 3 | Oct 23, 2025 | Hengrui Therapeutics, Inc. |
| NCT07187752 | N/A | Sep 30, 2025 | Shandong University |
| NCT07102381 | Phase 2 | Sep 24, 2025 | Jazz Pharmaceuticals |
| NCT07053085 | Phase 2 | Sep 17, 2025 | Gateway for Cancer Research, Memorial Sloan-Kettering Cancer Center |
| NCT07116824 | Phase 2 | Sep 15, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT07043725 | Phase 3 | Sep 15, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07136974 | Phase 2 | Sep 1, 2025 | Henan Medical University |
| NCT07095023 | N/A | Aug 15, 2025 | Guangdong Women and Children Hospital, Guangxi Medical University, Guizhou Medical University, Hainan People's Hospital, Peking University, Shantou University Medical College, Southern Medical University, Sun Yat-Sen University, Wenzhou Medical University |
| NCT07093931 | Phase 4 | Aug 1, 2025 | Chinese Academy of Medical Sciences, Shandong University |
| NCT07032298 | Phase 1 | Jul 18, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT07047755 | Phase 2 | Jul 1, 2025 | Henan Medical University |
| NCT07057427 | Phase 3 | Jun 24, 2025 | Henan Medical University |
| NCT07003074 | Phase 3 | Jun 23, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07108127 | Phase 2 | Jun 20, 2025 | Chinese Academy of Medical Sciences |
Showing 20 of 294 trials
Page 1 / 15
Organizations
Research & Development (254)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 69 | 39 | 4 | 2003 |
| Genentech | For profit | 40 | 15 | 4 | 2001 |
| National Cancer Institute (NCI) | Government | 17 | 8 | 4 | 2005 |
| Harvard University | Academic/Hospital | 10 | 9 | 2 | 2007 |
| Sun Yat-Sen University | Academic/Hospital | 10 | 5 | 3 | 2020 |
| Fudan University | Academic/Hospital | 9 | 7 | 3 | 2020 |
| AstraZeneca | For profit | 8 | 3 | 2 | 2016 |
| Henan Medical University | Academic/Hospital | 7 | 7 | 2 | 2020 |
| Pfizer | For profit | 6 | 0 | 2 | 2016 |
| Seattle Genetics | For profit | 6 | 1 | 3 | 2017 |
| University of South Florida | Academic/Hospital | 6 | 5 | 3 | 2011 |
| Amgen | For profit | 5 | 0 | 2 | 2014 |
| Cornell University | Academic/Hospital | 5 | 4 | 2 | 2011 |
| Hengrui Therapeutics, Inc. | For profit | 5 | 3 | 2 | 2020 |
| Merck | For profit | 5 | 1 | 2 | 2016 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 3 | 2 | 2021 |
| Daiichi Sankyo | For profit | 4 | 0 | 2 | 2020 |
| German Breast Group Forschungs GmbH | For profit | 4 | 3 | 2 | 2014 |
| Jiao Tong University | Academic/Hospital | 4 | 4 | 2 | 2020 |
| Novartis | For profit | 4 | 1 | 2 | 2014 |
254 organizations
Page 1 / 13
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Genentech | For profit | MKTG | Jun 8, 2012 |
| Genentech | For profit | NDA | Jun 8, 2012 |
| Genentech | For profit | SYN | Jun 29, 2020 |
| Roche | For profit | NDA2 | Jun 8, 2012 |
| Shanghai Henlius Biotech | For profit | MKTG | Nov 13, 2025 |